ArticleDiagnostic pathology2026
Pathomic model to predict the expression of UQCRH and overall survival of lung adenocarcinoma patients.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUbiquinol-cytochrome c reductase hinge protein (UQCRH) is a component of mitochondrial respiratory chain complex CIII. Its relationship with human cancer has been less studied. Pathomics uses artificial intelligence algorithms to collect histopathological image features and perform joint analysis by combining gene and transcriptome data. In this study, a pathomics prediction model was established based on UQCRH expression and histopathological images of lung adenocarcinoma (LUAD). Prognostic value and other analyses were conducted based on this model.
methodsThe expression level of UQCRH in 33 types of human cancers was measured. Its relationship with the survival of the primary LUAD samples with complete pathological images, gene expression data, and clinical information were divided into high and low expression groups based on the expression level threshold of the UQCRH gene (Table S1). LUAD patients was studied. Pathomic prediction model was established by using machine learning algorithms according to the UQCRH expression level and the characteristics of LUAD histopathological images. Based on this prediction model, survival analysis, molecular pathways, immune infiltration, immunological subtypes, ICI treatment prediction, and drug sensitivity analyses were performed.
resultsUQCRH is highly expressed in various cancers, including LUAD. In addition, we verified that UQCRH is overexpressed in human LUAD tissues. High expression of UQCRH is worse prognostic factor for LUAD patients. A pathomic prediction model was constructed based on the UQCRH expression level and histopathology image features. The pathomic score showed good correlation with the UQCRH expression level. Patients in the high-risk group of the pathomic prediction model had worse prognosis and higher tumor proliferation ability, but may have better response to immune checkpoint inhibitors (ICIs) therapy.
conclusionWe have established a pathomic prediction model for LUAD based on gene expression values and according to histopathological image features, which can predict patient survival prognosis and has potential guiding value for ICIs therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.